Ilevro (nepafenac)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Nepafenac is a prodrug of amfenac, a prototypical nonsteroidal anti-inflammatory agent (NSAIA) that also exhibits analgesic activity.
Nepafenac is a prodrug of amfenac, a prototypical nonsteroidal anti-inflammatory agent (NSAIA) that also exhibits analgesic activity. Following topical application to the eye, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, which inhibits the synthesis of prostaglandins by inhibiting cyclooxygenase (COX), including both COX-1 and COX-2 isoenzymes. The mechanism(s) of the ocular effects of NSAIAs appears to be associated principally with the inhibition of ocular prostaglandin synthesis.
By reducing ocular production of prostaglandins, NSAIAs can inhibit ocular inflammation and other reactions mediated primarily or secondarily by prostaglandins.
USES: This medication is used to relieve eye pain, irritation, and redness following cataract eye surgery. Nepafenac belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs). It works by blocking certain natural substances (prostaglandins) in your body that cause pain and swelling.
Generic name: nepafenac
Pronunciation: (ne-PA-fen-ak)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Ilevro
Indications
The following indications are listed for Ilevro:
- Post-Op Ocular Inflammation
- Postoperative Ocular Pain
Also known as: Post-Op Ocular Pain, Postoperative Eye Pain, Postoperative Ocular Inflammation, Postoperative Ophthalmic Inflammation.
Dosing
The recommended dosage of nepafenac for the treatment of pain and inflammation associated with cataract surgery in adults and children 10 years of age or older is 1 drop of a 0.1% suspension in the affected eye(s) 3 times daily beginning one day prior to cataract surgery and continuing on the day of the surgery and for 2 weeks after surgery.
Nepafenac is applied topically to the eye as an ophthalmic suspension. Care should be taken to avoid contamination of the suspension container.
Nepafenac ophthalmic suspension should be shaken well prior to administration. The suspension should not be administered while wearing contact lenses.
Nepafenac ophthalmic suspension may be used in conjunction with other topical ophthalmic medications such as beta-adrenergic blocking agents, carbonic anhydrase inhibitors, alpha-agonists, cycloplegics, and mydriatics. If the patient is receiving more than one topical ophthalmic drug, the drugs should be administered 10 minutes apart from nepafenac administration.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
Known hypersensitivity to nepafenac or any ingredient in the formulation or to other nonsteroidal anti-inflammatory agents (NSAIAs).
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
Adverse effects reported in 1% or more of patients receiving nepafenac ophthalmic suspension include capsular opacity, decreased visual acuity, ocular foreign body sensation, increased intraocular pressure, ocular sticky sensation, conjunctival edema, corneal edema, dry eye, lid margin crusting, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, photophobia, tearing, vitreous detachment, headache, hypertension, nausea, vomiting, and sinusitis.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
Safety and efficacy not established in children younger than 10 years of age.
Category C. (See Users Guide.) Avoid use in late pregnancy because of known effects on fetal cardiovascular system (possible closure of the ductus arteriosus).
Nepafenac (administered orally as a single 3-mg/kg dose) is distributed into milk in rats. It is not known whether nepafenac is distributed into human milk following topical application to the eye; caution if used in nursing women.
No substantial differences in safety and efficacy relative to younger adults.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.